{
    "organizations": [],
    "uuid": "74743df703ca67252da8080b7417a458bf805a93",
    "author": "",
    "url": "https://www.reuters.com/article/brief-strongbridge-biopharma-announces-d/brief-strongbridge-biopharma-announces-dosing-of-first-4-patients-in-logics-idUSFWN1RF06K",
    "ord_in_thread": 0,
    "title": "BRIEF-Strongbridge Biopharma Announces ‍Dosing of First 4 Patients In LOGICS",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2, 2018 / 11:49 AM / Updated 7 minutes ago BRIEF-Strongbridge Biopharma Announces ‍Dosing of First 4 Patients In LOGICS Reuters Staff 1 Min Read \nApril 2 (Reuters) - Strongbridge Biopharma plc: \n* ‍FIRST 4 PATIENTS HAVE BEEN DOSED IN LOGICS, A SECOND GLOBAL PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF RECORLEV​ Source text for Eikon: Further company coverage:",
    "published": "2018-04-02T14:48:00.000+03:00",
    "crawled": "2018-04-02T14:58:13.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "biopharma",
        "announces",
        "first",
        "patient",
        "logic",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "strongbridge",
        "biopharma",
        "plc",
        "patient",
        "dosed",
        "logic",
        "second",
        "global",
        "phase",
        "study",
        "evaluating",
        "efficacy",
        "safety",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}